menu
    • menu

    Company profile for ChemExpress

    Mix Gif-PSE
    News
    A New Paradigm for ADC R&D Strategic Collaboration Announced

    24 Oct 2025

    // PRESS RELEASE

    ChemExpress Mabwell And Insilico Partner To Boost ADC Innovation

    22 Sep 2025

    // PRESS RELEASE

    China's ADC/XDC Pipeline Fuels Global Breakthroughs

    12 Sep 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    #1

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/nEydgaZwXlA?si=B-64pbxiXUKRnM0O

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    PharmaCompass

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Related CompaniesRelated Companies

    About

    Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ChemExpressChina Flag
    Country
    Country
    China
    Address
    Address
    No. 3 Building, No. 1999, Zhangheng Road,Pudong New Area, Shanghai
    Telephone
    Telephone
    +86 2158950125
    Client Email
    Email
    info@chemexpress.com
    Client Website
    Website
    https://www.chemexpress.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/haoyuan-chemexpress-co-ltd/
    youtube
    YouTube
    http://www.youtube.com/@ChemExpress-mkt
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/haoyuan-chemexpress-coltd-party-content-12610.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    ADC Small Molecule Product Handbook

    read-more

      https://www.pharmacompass.com/pdf/party/content/haoyuan-chemexpress-coltd-party-content-86814.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Services Brochure

    read-more

      https://www.pharmacompass.com/pdf/party/content/haoyuan-chemexpress-coltd-party-content-56108.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    DMF filings rise 4.5% in Q3 2025; China holds lead, India records 20% growth in submissions

    The third quarter (Q3) of 2025 witnessed a steady rise in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA). DMFs are used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug productsA total of 323 Type II DMFs were submitted during this period, as opposed to 309 submissions in Q3 2024, marking an increase of 4.53 percent. This is the second highest number since 2018. In Q1 2025, 339 Type II filings were recorded.Across all DMF types (II, III, IV, and V), 479 DMFs were filed in Q3 2025, compared to 394 in Q3 2024, representing a 21.57 percent increase. Out of the 323 Type II DMFs submitted in Q3 2025, 40 had completed their review by the end of Q3, reflecting a processing lag between submission and review completion. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available)China maintains its lead while India posts double-digit growth in DMF submissions China and India continued to dominate DMF submissions in Q3 2025. China retained the top spot with 153 Type II DMFs, matching its submission count from Q3 2024. India recorded 131 DMFs, marking a 20.18 percent increase over 109 filings during the corresponding period last year.The United States stood a distant third with 17 filings, compared to 13 in Q3 2024. Among European nations, Italy recorded eight DMFs, doubling its 2024 tally. The Netherlands filed four, up from three. Spain submitted only one DMF, as against seven submitted in Q3 2024. Taiwan made three filings, up from one submitted in Q3 2024. Together, India, China and Taiwan accounted for about 88.9 percent of all Type II DMFs filed during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) China’s Suzhou Ryway Biotech tops corporate tally; India’s Hetero, Biophore followChina’s Suzhou Ryway Biotech led the company-wise tally with 12 DMF submissions in Q3 2025. The company had not filed any DMFs in Q3 2024.India’s Hetero Group followed with nine DMFs, maintaining the same number of filings as Q3 2024. Biophore India Pharmaceuticals ranked third with six DMFs, doubling its count from three last year.Other notable contributors include Sai Sreyas Pharmaceuticals (India) and Shanghai Haoyuan Chemexpress (China), with five DMFs each. Companies such as SNJ Group, Lunan Pharmaceutical, Allsino Pharmaceutical, Shankus Pharma, Jiangxi Xinganjiang Pharmaceutical, Sunpure Extracts, Lee Pharma, Umedica Laboratories, Linhai Tianyu Pharmaceutical and Maithri Drugs filed four DMFs each. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) Olaparib, semaglutide lead molecular filings; Dr. Reddy’s files DMF for edoxaban & tucatinibDr. Reddy’s Laboratories also featured among key DMF filers in Q3 2025, submitting two DMFs — for edoxaban tosylate monohydrate and tucatinib copovidone. Edoxaban tosylate monohydrate (marketed as Savaysa by Daiichi Sankyo) is a prescription anticoagulant used to reduce the risk of stroke and to treat deep vein thrombosis and pulmonary embolism. Patent exclusivity for Savaysa extends until October 2026 in the United States, with no generic currently available.In terms of molecules, the highest number of DMFs were filed for olaparib, semaglutide, ruxolitinib phosphate, ferric carboxymaltose, and vismodegib, with three DMFs each in Q3 2025.Olaparib, sold by AstraZeneca under the brand name Lynparza, saw DMFs being filed by BDR Lifesciences and Intas Pharmaceuticals from India, and by ScinoPharm Taiwan during the quarter.Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, continued to draw strong interest from API manufacturers. DMFs for semaglutide were filed by three Chinese companies: Yangzhou Aurisco Pharmaceutical, Zhejiang Peptites Biotech, and Fujian Genohope Biotech.Ruxolitinib phosphate, marketed by Incyte as Jakafi, saw three DMFs. Three Indian companies — Alembic Pharmaceuticals, Valary Labs, and Devi Pharmatech — filed DMFs for this API in Q3 2025. Other molecules that received multiple DMF submissions include ferric carboxymaltose (used to treat iron-deficiency anemia) and vismodegib (an oral therapy for basal-cell carcinoma). View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) First-time DMF filings span 17 companies; India leads with nine first-time DMFs The quarter saw first-time DMF filings from 17 companies. India took a lead here with nine first-time DMF filings, followed by China (six), and the US (two).The DMF filings in this quarter included inclisiran sodium (filed by Aurisco Pharmaceutical of China), pacritinib citrate (by TAPI Nl B.V. of the Netherlands), and vosoritide (by Apicore LLC of the US).Out of the 19 first-time DMFs filed in Q3 2025, four completed their Generic Drug User Fee Amendments (GDUFA) review process during the quarter. View FDA DMF Filings in Q3 2025 (Power BI Dashboard, Free Excel Available) GDUFA fee for FY 2026: The FDA Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry.Fee rates for fiscal year 2026 were published on July 30, 2025. FDA has revised fees under GDUFA III across all categories. While there is a slight increase in the DMF fee from US$ 95,084 in 2025 to US$ 102,584 in 2026, the ANDA fee has seen a sharp rise: from US$ 321,920 in 2025 to US$ 358,247 in 2026.FY 2025 and FY 2026 User Fee Rates Generic drug fee category Fees rates for FY 2025 Fees rates for FY 2026 Applications:     Abbreviated New Drug Application (ANDA) US$ 3,21,920 US$ 3,58,247 Drug Master File (DMF) US$ 95,084 US$ 1,02,584 Facilities:     Active Pharmaceutical Ingredient (API)—Domestic US$ 41,580 US$ 43,549 API—Foreign US$ 56,580 US$ 58,549 Finished Dosage Form (FDF)—Domestic US$ 2,31,952 US$ 2,38,943 FDF—Foreign US$ 2,46,952 US$ 2,53,943 Contract Manufacturing Organization (CMO)—Domestic US$ 55,668 US$ 57,346 CMO—Foreign US$ 70,668 US$ 72,346 GDUFA Program:     Large size operation generic drug applicant US$ 18,91,664 US$ 19,18,377 Medium size operation generic drug applicant US$ 7,56,666 US$ 7,67,351 Small business generic drug applicant US$ 1,89,166 US$ 1,91,838 Our viewFor several years prior to the pandemic, India had a lead in Type II DMF submissions. In recent years, China has surpassed India in DMF filings. But Q3 2025 numbers indicate that Indian drugmakers are fast catching up. Since DMFs establish trust in APIs from across the world, we feel this healthy competition between drugmakers from the two countries is good for the global pharmaceutical industry. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2944

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions

    #PharmaFlow by PHARMACOMPASS
    13 Nov 2025
    Share Share
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3154

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    A New Paradigm for ADC R&D Strategic Collaboration Announced
    A New Paradigm for ADC R&D Strategic Collaboration Announced

    24 Oct 2025

    // PRESS RELEASE

    https://www.chemexpress.com/news-and-events/news/adc-ai-biotech-cdmo-collaboration

    PRESS RELEASE
    24 Oct 2025
    Share Share
    ChemExpress Mabwell And Insilico Partner To Boost ADC Innovation
    ChemExpress Mabwell And Insilico Partner To Boost ADC Innovation

    22 Sep 2025

    // PRESS RELEASE

    https://www.chemexpress.com/newsletter/ai-powered-adc-drug-development

    PRESS RELEASE
    22 Sep 2025
    Share Share
    China's ADC/XDC Pipeline Fuels Global Breakthroughs
    China's ADC/XDC Pipeline Fuels Global Breakthroughs

    12 Sep 2025

    // PRESS RELEASE

    https://www.chemexpress.com/newsletter/ADC-XDC

    PRESS RELEASE
    12 Sep 2025
    Share Share
    Peptide Therapeutics Enter Golden Era of Drug Development
    Peptide Therapeutics Enter Golden Era of Drug Development

    28 Aug 2025

    // PRESS RELEASE

    https://www.chemexpress.com/newVisotation/176

    PRESS RELEASE
    28 Aug 2025
    Share Share
    DAC: A Game-Changer for Undruggable Targets
    DAC: A Game-Changer for Undruggable Targets

    15 Aug 2025

    // PRESS RELEASE

    https://www.chemexpress.com/newVisotation/177

    PRESS RELEASE
    15 Aug 2025
    Share Share
    Breakthroughs in KRAS Inhibitor Scaffolds
    Breakthroughs in KRAS Inhibitor Scaffolds

    16 May 2025

    // PRESS RELEASE

    https://www.chemexpress.com/newsletter/EcoVadis-2025

    PRESS RELEASE
    16 May 2025
    Share Share

    ALL Intermediates

    read-more
    read-more
    Contact Supplier
      • fda
      • EDQM
      • WHO-GMP
      Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

      247068-85-5

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      247068-85-5
      Carfilzomib
      Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
      Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
      Company Banner

      01

      247068-85-5

      China
      Biotech Showcase
      Not Confirmed
      arrow
      • fda
      • EDQM
      • WHO-GMP
      Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

      ChemExpress

      247068-85-5

      CAS Number : 247068-85-5

      End Use API : Carfilzomib

      About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

      Company Banner

      Intermediate Web Link

      Market Place

      Contact Supplier
        • fda
        • EDQM
        • WHO-GMP
        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

        157322-83-3

        Intermediate Web Link

        Market Place

        157322-83-3
        Eribulin
        Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
        Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
        Company Banner

        02

        157322-83-3

        China
        Biotech Showcase
        Not Confirmed
        arrow
        • fda
        • EDQM
        • WHO-GMP
        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

        ChemExpress

        157322-83-3

        CAS Number : 157322-83-3

        End Use API : Eribulin

        About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

        Company Banner

        Intermediate Web Link

        Market Place

        Contact Supplier
          • fda
          • EDQM
          • WHO-GMP
          Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

          157322-47-9

          Intermediate Web Link

          Market Place

          157322-47-9
          Eribulin
          Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
          Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
          Company Banner

          03

          157322-47-9

          China
          Biotech Showcase
          Not Confirmed
          arrow
          • fda
          • EDQM
          • WHO-GMP
          Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

          ChemExpress

          157322-47-9

          CAS Number : 157322-47-9

          End Use API : Eribulin

          About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

          Company Banner

          Intermediate Web Link

          Market Place

          Contact Supplier
            • fda
            • EDQM
            • WHO-GMP
            Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

            733039-20-8

            Intermediate Web Link

            Market Place

            733039-20-8
            Palbociclib
            Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
            Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
            Company Banner

            04

            733039-20-8

            China
            Biotech Showcase
            Not Confirmed
            arrow
            • fda
            • EDQM
            • WHO-GMP
            Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

            ChemExpress

            733039-20-8

            CAS Number : 733039-20-8

            End Use API : Palbociclib

            About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

            Company Banner

            Intermediate Web Link

            Market Place

            Contact Supplier
              • fda
              • EDQM
              • WHO-GMP
              Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

              1013916-37-4

              Intermediate Web Link

              Market Place

              1013916-37-4
              Palbociclib
              Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
              Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
              Company Banner

              05

              1013916-37-4

              China
              Biotech Showcase
              Not Confirmed
              arrow
              • fda
              • EDQM
              • WHO-GMP
              Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

              ChemExpress

              1013916-37-4

              CAS Number : 1013916-37-4

              End Use API : Palbociclib

              About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

              Company Banner

              Intermediate Web Link

              Market Place

              Contact Supplier
                • fda
                • EDQM
                • WHO-GMP
                Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                1016636-76-2

                Intermediate Web Link

                Market Place

                1016636-76-2
                Palbociclib
                Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
                Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
                Company Banner

                06

                1016636-76-2

                China
                Biotech Showcase
                Not Confirmed
                arrow
                • fda
                • EDQM
                • WHO-GMP
                Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                ChemExpress

                1016636-76-2

                CAS Number : 1016636-76-2

                End Use API : Palbociclib

                About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

                Company Banner

                Intermediate Web Link

                Market Place

                Contact Supplier
                  • fda
                  • EDQM
                  • WHO-GMP
                  Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                  571189-16-7

                  Intermediate Web Link

                  Market Place

                  571189-16-7
                  Palbociclib
                  Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
                  Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
                  Company Banner

                  07

                  571189-16-7

                  China
                  Biotech Showcase
                  Not Confirmed
                  arrow
                  • fda
                  • EDQM
                  • WHO-GMP
                  Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                  ChemExpress

                  571189-16-7

                  CAS Number : 571189-16-7

                  End Use API : Palbociclib

                  About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

                  Company Banner

                  Intermediate Web Link

                  Market Place

                  Contact Supplier
                    • fda
                    • EDQM
                    • WHO-GMP
                    Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                    571188-59-5

                    Intermediate Web Link

                    Market Place

                    571188-59-5
                    Palbociclib
                    Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
                    Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
                    Company Banner

                    08

                    571188-59-5

                    China
                    Biotech Showcase
                    Not Confirmed
                    arrow
                    • fda
                    • EDQM
                    • WHO-GMP
                    Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                    ChemExpress

                    571188-59-5

                    CAS Number : 571188-59-5

                    End Use API : Palbociclib

                    About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

                    Company Banner

                    Intermediate Web Link

                    Market Place

                    Contact Supplier
                      • fda
                      • EDQM
                      • WHO-GMP
                      Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                      571188-82-4

                      Intermediate Web Link

                      Market Place

                      571188-82-4
                      Palbociclib
                      Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
                      Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
                      Company Banner

                      09

                      571188-82-4

                      China
                      Biotech Showcase
                      Not Confirmed
                      arrow
                      • fda
                      • EDQM
                      • WHO-GMP
                      Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                      ChemExpress

                      571188-82-4

                      CAS Number : 571188-82-4

                      End Use API : Palbociclib

                      About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

                      Company Banner

                      Intermediate Web Link

                      Market Place

                      Contact Supplier
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        866084-31-3

                        Intermediate Web Link

                        Market Place

                        866084-31-3
                        Palbociclib
                        Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies....
                        Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
                        Company Banner

                        10

                        866084-31-3

                        China
                        Biotech Showcase
                        Not Confirmed
                        arrow
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        ChemExpress

                        866084-31-3

                        CAS Number : 866084-31-3

                        End Use API : Palbociclib

                        About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company support...

                        Company Banner

                        Intermediate Web Link

                        Market Place

                        Only 10 entries up to this point, click to access all click full view read-more
                        click full view
                        Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

                        KEY PRODUCTS

                        read-more
                        read-more

                        TOP RANKED SUPPLIER FOR:

                        Sponsored Ads.
                        full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view
                        Sponsored Ads.full-view

                        Services

                        Discover the service capabilities from this company

                        API Manufacturing

                        Discover their expertise for : API Manufacturing

                        Drug Product Manufacturing

                        Discover their expertise for : Drug Product Manufacturing

                        API & Drug Product Development

                        Discover their expertise for : API & Drug Product Development

                        API Development

                        read-more
                        read-more

                        01

                        CDMO FOR HPAPIs

                        China
                        Contact Supplier
                        arrow
                        BIO Partnering at JPM
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        ChemExpress

                        ChemExpress is a CDMO that offers HPAPI development and manufacturing services. It has 5 GMP HPAPI production lines (OEB5, OEL 0.01 μg/m³) with a total volume of over 4,000 L, capable of scaling up to commercial-scale kilogram quantities.

                        arrow

                        Category : API Development

                        Sub Category : High Potency APIs (HPAPIs)

                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        CDMO FOR HPAPIs

                        ChemExpress is a CDMO that offers HPAPI development and manufacturing services. It has 5 GMP HPAPI production lines (OEB5, OEL 0.01 μg/m³) with a total volume of over 4,000 L, capable of scaling up to commercial-scale kilogram quantities.

                        arrow
                        CDMO for HPAPIs

                        Service
                        Web Link

                        Capabilities
                        #ServicesBio

                        Market
                        Place

                        02

                        CDMO FOR PEPTIDES

                        China
                        Contact Supplier
                        arrow
                        BIO Partnering at JPM
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        ChemExpress

                        ChemExpress provides flexible peptide service models, including FTE/FFS, process development, CMC, and CDMO solutions. Our capabilities cover high-throughput synthesis, custom synthesis, peptide modification, and GMP manufacturing.

                        arrow

                        Category : API Development

                        Sub Category : Protein / Peptide

                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        CDMO FOR PEPTIDES

                        ChemExpress provides flexible peptide service models, including FTE/FFS, process development, CMC, and CDMO solutions. Our capabilities cover high-throughput synthesis, custom synthesis, peptide modification, and GMP manufacturing.

                        arrow
                        CDMO for Peptides

                        Service
                        Web Link

                        Capabilities
                        #ServicesBio

                        Market
                        Place

                        03

                        CDMO FOR APIs

                        China
                        Contact Supplier
                        arrow
                        BIO Partnering at JPM
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        ChemExpress

                        ChemExpress has a highly experienced and qualified team for the synthesis of a variety of compounds and new modalities, including but not limited to small molecules, antibody-drug conjugates (ADCs), PROTACs, peptides, and oligonucleotides.

                        arrow

                        Category : API Development

                        Sub Category : Overview

                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        CDMO FOR APIs

                        ChemExpress has a highly experienced and qualified team for the synthesis of a variety of compounds and new modalities, including but not limited to small molecules, antibody-drug conjugates (ADCs), PROTACs, peptides, and oligonucleotides.

                        arrow
                        CDMO for APIs

                        Service
                        Web Link

                        Capabilities
                        #ServicesBio

                        Market
                        Place

                        Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

                        Formulation Development

                        read-more
                        read-more

                        01

                        FORMULATION DEVELOPMENT SERVICES

                        China
                        Contact Supplier
                        arrow
                        BIO Partnering at JPM
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        ChemExpress

                        ChemExpress offers various formulation developments of new dosage forms, along with process scale-up and technology transfer. It also offers analytical method development, stability studies, and lifecycle management.

                        arrow

                        Category : Formulation Development

                        Sub Category : Overview

                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        FORMULATION DEVELOPMENT SERVICES

                        ChemExpress offers various formulation developments of new dosage forms, along with process scale-up and technology transfer. It also offers analytical method development, stability studies, and lifecycle management.

                        arrow
                        Formulation Development Services

                        Service
                        Web Link

                        Capabilities
                        #ServicesBio

                        Market
                        Place

                        02

                        CDMO FOR TABLETS

                        China
                        Contact Supplier
                        arrow
                        BIO Partnering at JPM
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        ChemExpress

                        ChemExpress is a CRO/CDMO that offers various oral solid dosage forms such as granules, powders, and tablets, with a capacity of 1 billion tablets per year.

                        arrow

                        Category : Formulation Development

                        Sub Category : Tablet

                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        CDMO FOR TABLETS

                        ChemExpress is a CRO/CDMO that offers various oral solid dosage forms such as granules, powders, and tablets, with a capacity of 1 billion tablets per year.

                        arrow
                        CDMO for Tablets

                        Service
                        Web Link

                        Capabilities
                        #ServicesBio

                        Market
                        Place

                        03

                        TOPICAL FORMULATION DEVELOPMENT

                        China
                        Contact Supplier
                        arrow
                        BIO Partnering at JPM
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        ChemExpress

                        ChemExpress is a CDMO that offers formulation development of various topical semi-solid dosage forms such as gels, creams, and ointments.

                        arrow

                        Category : Formulation Development

                        Sub Category : Cream / Gel / Lotion / Ointment

                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        TOPICAL FORMULATION DEVELOPMENT

                        ChemExpress is a CDMO that offers formulation development of various topical semi-solid dosage forms such as gels, creams, and ointments.

                        arrow
                        Topical Formulation Development

                        Service
                        Web Link

                        Capabilities
                        #ServicesBio

                        Market
                        Place

                        04

                        FORMULATION DEVELOPMENT OF CAPSULES

                        China
                        Contact Supplier
                        arrow
                        BIO Partnering at JPM
                        Not Confirmed
                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        ChemExpress

                        ChemExpress is a CRO/CDMO that offers various oral solid dosage forms such as granules, powders, and capsules, with a capacity of 500 million capsules per year.

                        arrow

                        Category : Formulation Development

                        Sub Category : Capsule

                        • fda
                        • EDQM
                        • WHO-GMP

                        Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

                        Pharma Service : API & Drug Product Development

                        FORMULATION DEVELOPMENT OF CAPSULES

                        ChemExpress is a CRO/CDMO that offers various oral solid dosage forms such as granules, powders, and capsules, with a capacity of 500 million capsules per year.

                        arrow
                        Formulation Development of Capsules

                        Service
                        Web Link

                        Capabilities
                        #ServicesBio

                        Market
                        Place

                        Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

                        KEY SERVICES

                        read-more
                        read-more

                        TOP RANKED SUPPLIER FOR:

                        Pop up full-view
                        End-to-end CDMO for ADCs
                        full-view
                        cGMP Contract Manufacturing of API
                        full-view
                        Custom Synthesis and Process Development
                        full-view
                        Custom Peptide Synthesis Services
                        full-view
                        Small Molecule API Contract Manufacturing
                        full-view

                        ABOUT THIS PAGE

                        Contact ChemExpress and get a quotation

                        ChemExpress is a supplier offers 35 products (APIs, Excipients or Intermediates).

                        Find a price of Eribulin bulk with DMF offered by ChemExpress

                        Find a price of Trabectedin bulk with DMF offered by ChemExpress

                        Find a price of Avibactam Sodium bulk offered by ChemExpress

                        Find a price of Axitinib bulk offered by ChemExpress

                        Find a price of Baloxavir Marboxil bulk offered by ChemExpress

                        Find a price of Bazedoxifene Acetate bulk offered by ChemExpress

                        Find a price of Bifonazole bulk offered by ChemExpress

                        Find a price of Calcipotriol bulk offered by ChemExpress

                        Find a price of Crisaborole bulk offered by ChemExpress

                        Find a price of Doxcercalciferol bulk offered by ChemExpress

                        Find a price of Doxorubicin Hydrochloride bulk offered by ChemExpress

                        Find a price of Duocarmycin TM bulk offered by ChemExpress

                        Find a price of Elobixibat bulk offered by ChemExpress

                        Find a price of Eluxadoline bulk offered by ChemExpress

                        Find a price of Exatecan bulk offered by ChemExpress

                        Find a price of Fexuprazan bulk offered by ChemExpress

                        Find a price of Flibanserin bulk offered by ChemExpress

                        Find a price of Ilaprazole bulk offered by ChemExpress

                        Find a price of Ilaprazole Sodium bulk offered by ChemExpress

                        Find a price of Lenacapavir bulk offered by ChemExpress

                        Find a price of Lurbinectedin bulk offered by ChemExpress

                        Find a price of Lurtotecan bulk offered by ChemExpress

                        Find a price of Maytansinol bulk offered by ChemExpress

                        Find a price of Palbociclib bulk offered by ChemExpress

                        Find a price of Pitolisant Hydrochloride bulk offered by ChemExpress

                        Find a price of Ribociclib bulk offered by ChemExpress

                        Find a price of Sacubitril-Valsartan bulk offered by ChemExpress

                        Find a price of Tacalcitol bulk offered by ChemExpress

                        Find a price of Tegoprazan bulk offered by ChemExpress

                        Find a price of Teneligliptin Hydrobromide bulk offered by ChemExpress

                        Find a price of Ticagrelor bulk offered by ChemExpress

                        Find a price of Triptolide bulk offered by ChemExpress

                        Find a price of Tubulysin A bulk offered by ChemExpress

                        Find a price of Vatiquinone bulk offered by ChemExpress

                        Find a price of Vonoprazan Fumarate bulk offered by ChemExpress

                        Ask Us for Pharmaceutical Supplier and Partner
                        Ask Us, Find A Supplier / Partner
                        No Commissions, No Strings Attached, Get Connected for FREE

                        What are you looking for?

                        How can we help you?

                        The request can't be empty

                        Please read our Privacy Policy carefully

                        You must agree to the privacy policy

                        The name can't be empty
                        The company can't be empty.
                        The email can't be empty Please enter a valid email.
                        The mobile can't be empty
                        • Privacy policy
                        • Terms and conditions
                        • Disclaimers
                        • LinkedIn
                        • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

                        Market Place

                        Market Place

                        PharmaCompass

                        Home

                        Market Place

                        Menu

                        Post Enquiry

                        Post Enquiry

                        Market Place

                        Market Place

                        Search